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The red scaly skin of patients with psoriasis 
is caused by a complex circuit of in-
flammatory cells and cytokines. Zaba et al. 
(page 3183) now find that switching off 
one type of T helper (Th) cell is enough 
to break the circuit and heal the 
lesions.
Th1 cells that secrete interferon 
(IFN)-γ were initially thought to be the 
main villains within psoriatic plaques—
build-ups of overproliferating skin cells. 
In animal models of psoriasis, IFN-γ 
thickens plaques by further increasing 
the proliferation of skin cells and enhancing 
their production of chemokines that re-
cruit inflammatory cells.
But cytokines other than IFN-γ 
may be more to blame. Inhibitors of 
tumor necrosis factor (TNF)—originally 
given to patients to treat Crohn’s dis-
ease and other inflammatory illnesses—
have been shown to alleviate psoriasis-
like lesions. How they work, however, 
was unclear.
Zaba et al. now find that blocking 
TNF prevents psoriasis by inactivating 
Th17 cells. Th17 cells are normally ac-
tivated by TNF-stimulated dendritic 
cells (DCs) and induce epithelial cell 
proliferation by secreting IL-22. But 
fewer DCs and lower levels of IL-22 
were found in treated plaques, which 
disappeared after two weeks of treat-
ment with the TNF blocker.
Immediate relief from psoriasis 
might thus be made possible by getting 
rid of Th17 cells. Future studies might 
therefore benefit from focusing on 
Th17 cells rather than on Th1 cells, 
which survive in the plaques weeks 
longer than Th17 cells but fail to per-
petuate disease. HB
Skin DCs go deeper
Skin dendritic cells (DCs), called Langerhans cells (LCs), reside in the 
epidermis, where they express a lectin called langerin. Although DCs 
were also known to reside in the dermis, these cells were not thought 
to express langerin. But three reports by Bursch et al. (page 3147), 
Poulin et al. (page 3119), and Ginhoux et al. (page 3133) now show 
that a subset of langerin-expressing DCs call the dermis home.
The new cells were discovered in mice whose own bone marrow 
had been eliminated by irradiation and replaced with donor bone 
marrow. The irradiation eliminates all immune cells except for 
epidermal LCs. Six weeks after bone marrow transplant, Bursch et al. 
found that epidermal LCs were primarily from the host, as expected. 
But they also found donor-derived DCs that expressed langerin in 
the dermis and lymph nodes. These new DCs were also spotted 
circulating in the blood by Ginhoux et al. and in the lung and liver by 
Poulin et al. The latter group showed that the dermal langerin+ DCs 
expressed surface markers distinct from those expressed by classic LCs.
The dermal DCs repopulated the skin more rapidly than LCs after toxin-induced DC elimination, according 
to Bursch et al. This finding may explain prior DC depletion studies, which showed that allergic skin reactions—
thought to require T cell activation by epidermal LCs—occurred before the LCs could repopulate the skin.
The precise role of the new langerin+ DCs is not yet clear. They have been seen clustering around 
hair follicles in the upper dermis, which may give them access to antigens that do not penetrate more 
deeply. Their rapid renewal and trafficking to lymph nodes might also be important in protecting the 
dermis against infection when the epidermis is injured. What these cells are doing in the lung and the 
liver, however, is a bigger mystery. RR
TNF (green) stimulates dendritic cells 
(red) that cause psoriasis-like lesions 
(top). Lesions can be relieved by a TNF 
blocker (bottom).
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A new subset of dendritic cells (arrows) is found in the dermis.